Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nektar Turns Up The Heat On Partnering Talks For NKTR-181

Executive Summary

The company reported positive Phase III efficacy data on the first-in-class mu-opioid agonist molecule designed to provide pain relief without the euphoria that leads to addiction with standard opioids.


Related Content

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue
Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
FDA Moves On Endo’s Opana ER Unlikely To Sweep Up Other Opioids
Purdue Is Open For Business Deals And Shopping On Multiple Fronts


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts